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ABSTRACT
The idea that some phenotypes bear a closer relationship to the biological processes that give rise to
psychiatric illness than diagnostic categories has attracted considerable interest. Much eﬀort has
been devoted to ﬁnding such endophenotypes, partly because it is believed that the genetic basis of
endophenotypes will be easier to analyse than that of psychiatric disease. This belief depends in part
on the assumption that the eﬀect sizes of genetic loci contributing to endophenotypes are larger
than those contributing to disease susceptibility, hence increasing the chance that genetic linkage
and association tests will detect them. We examine this assumption by applying meta-analytical
techniques to genetic association studies of endophenotypes. We ﬁnd that the genetic eﬀect sizes of
the loci examined to date are no larger than those reported for other phenotypes. A review of the
genetic architecture of traits in model organisms also provides no support for the view that the eﬀect
sizes of loci contributing to phenotypes closer to the biological basis of disease is any larger than
those contributing to disease itself. While endophenotype measures may aﬀord greater reliability, it
should not be assumed that they will also demonstrate simpler genetic architecture.
Introduction
This review examines what is known about the
genetic architecture of endophenotypes and as-
sesses the claim that endophenotypes are more
suitable than psychiatric diagnostic categories
for genetic dissection, by which we mean the
application of genetic linkage and association
strategies to identify genes associated with psy-
chiatric disease and component mechanisms.
We start with a brief introduction to endo-
phenotypes and then proceed to examine
examples where suﬃcient genetic data have ac-
cumulated for our purpose. We do not provide a
comprehensive review of all endophenotypes
employed in psychiatric genetics.
The concept of the endophenotype was in-
troduced to psychiatry over 30 years ago by
Gottesman & Shields (1973), but its popularity
is more recent: there are eight PubMed entries
before 2000 compared to 150 in the current
century. Gottesman & Shields (1973) adapted
the term from a 1966 paper that attributed the
geographical distribution of grasshoppers to the
insects’ ‘endophenotype’ (John & Lewis, 1966),
a neologism alluding to a phenotype that was
microscopic and internal, and therefore obscure
to casual observation. Endophenotypes in psy-
chiatry retain the notion of an internal process,
but one that can be objectively measured, ideally
in a robust and reliable fashion, a characteristic
often lacking in the diseases with which they are
associated.
Gottesman’s deﬁnition of an endophenotype
is that it should be heritable, co-segregate with a
psychiatric illness, yet be present even when the
disease is not (i.e. state independent), and be
found in non-aﬀected family members at a
higher rate than in the population (Gottesman
& Gould, 2003). The criterion of state indepen-
dence was modiﬁed to take into account the
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163importance of epigenetic and developmental
factors so that the endophenotype can be
manifest only at a certain age and/or after a
challenge (in the same way that a glucose
challenge is used for a glucose tolerance test)
(Hasler et al. 2006). Others have added criteria
that require endophenotypes to be part of the
causal process by which disease arises (Lavori
et al. 2002), or at least be involved in a biologi-
cally plausible mechanism of pathogenesis
(Tsuang et al. 1993; Castellanos & Tannock,
2002), or, following Almasy & Blangero (2001),
require that an endophenotype ‘should be con-
tinuously quantiﬁable, should predict disorder
probabilistically and should be closer to the site
of primary causative agent (whether genetic or
environmental) than to diagnostic categories’.
It has also been suggested, that ‘priority
should be given to endophenotypes that are
based or anchored in neuroscience’ (Doyle et al.
2005).
Table 1 lists commonly investigated endo-
phenotypes in psychiatry and reveals a number
of features. First, a small number of endo-
phenotypes have attracted disproportionate
attention. Second, work on many endo-
phenotypes often predates the development of
the endophenotype concept and goes beyond
its concern with genetics. Interest in endo-
phenotypes reﬂects a longstanding interest in
investigating the biological correlates of psychi-
atric disease. Third, endophenotypes can be
categorized into six groups: anatomical, devel-
opmental, electrophysiological, metabolic, sen-
sory or psychological/cognitive. Fourth, we
identiﬁed papers claiming endophenotypes for
just seven psychiatric disorders. Together, these
observations indicate that there is plenty of
scope to ﬁnd new endophenotypes in psychiatry,
both by analysis of other psychiatric disorders
and by searching for new features that have the
relevant characteristics.
One important reason for the popularity
of endophenotypes is that they are believed to
improve the chances of detecting at a molecular
level the genetic variants that contribute to dis-
ease susceptibility (Freimer & Sabatti, 2003,
2004). We can summarize the argument as
follows: endophenotypes provide a genetically
tractable target, one that lies in the gap between
gene and disease process, so that by dissect-
ing their genetic basis we would understand
something about the biology of a psychiatric
disease. An example will clarify the idea.
Consider the diﬃculties of determining the
molecular basis of schizophrenia. We have con-
vincing evidence from twin, family and adop-
tion studies that there is a substantial genetic
contribution to the illness (Kendler & Diehl,
1993). Although diagnosis is not easy, the limi-
tations of the diagnostic categories and the
potential overlaps with other disorders are
appreciated. Consequently we can categorize
patients in ways that allow genetic analysis.
Nevertheless, mapping genetic determinants by
linkage or identifying genetic variants by as-
sociation has proved extremely diﬃcult, an ob-
servation that can be explained by assuming
that schizophrenia has a complex genetic archi-
tecture, consisting of multiple genetic eﬀects
that individually alter susceptibility by a small
degree and operate via interactions with each
other and the environment (Riley & Kendler,
2006). The complex genetic architecture means
that gene ﬁnding, using current methodologies,
is extremely hard. Despite an enormous and
rapidly growing molecular genetic literature,
only a handful of candidate genes have been
identiﬁed and there remains considerable con-
troversy regarding the reliability of these ﬁnd-
ings (Riley & Kendler, 2006).
An attractive alternative is to work with
endophenotypes because ‘endophenotypes rep-
resent more deﬁned and quantiﬁable measures
that are envisioned to involve fewer genes, fewer
interacting levels and ultimately activation of a
single set of neuronal circuits. The fewer the
pathways that give rise to an endophenotype,
the better the chances of eﬃciently discovering
its genetic and neurobiological underpinnings’
(Gottesman & Gould, 2003). In short, the gen-
etic basis of endophenotypes is assumed to be
less complicated than that of their cognate psy-
chiatric illness, their genetic determination is
more direct, and, in consequence, they are
potentially more tractable to genetic dissection
than the disease states themselves. This pre-
sumption is made in most papers that seek to
document endophenotypes, but has not so far
been rigorously tested, due in large part to
the paucity of relevant genetic studies. Our aim
in this review is to ﬁnd out whether the genetic
basis of endophenotypes is indeed more
tractable to genetic dissection than that of
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Disease Type of deﬁcit Endophenotype measure Reference
ADHD Psychological Attention deﬁcits (measured by the CPT) Oh et al. (2003)
ADHD Psychological Delay gradients, temporal processing,
working memory
Castellanos & Tannock (2002)
ADHD Psychological Executive performance: response inhibition Slaats-Willemse et al. (2003)
Alcoholism Electrophysiological EEG coherence (cortical synchronization) Winterer et al. (2003)
Alcoholism Electrophysiological Oscillatory correlates during cognitive
processing
Kamarajan et al. (2004)
Alcoholism Electrophysiological Event-related potential: P300 amplitude Prabhu et al. (2001); Carlson et al. (2002)
Anxiety Metabolic Cortisol secretion Goldsmith & Lemery (2000)
Anxiety Psychological Perception of aﬀect Bolte & Poustka (2003)
Anxiety Psychological Personality Smoller & Tsuang (1998)
Autism Developmental Age at ﬁrst word Alarcon et al. (2002, 2003)
Autism Psychological Spatial memory deﬁcits Koczat et al. (2002)
Bipolar disorder Anatomical MRI hyperintensities Ahearn et al. (2002)
Bipolar disorder Metabolic Circadian rhythm Benedetti et al. (2004)
Bipolar disorder Metabolic Basal intracellular calcium levels Yoon et al. (2001)
Bipolar disorder Metabolic Reduced 5-HTT function Leboyer et al. (1999)
Bipolar disorder Psychological Response to tryptophan depletion Quintin et al. (2001); Sobczak et al. (2002)
Bipolar disorder Psychological Prefrontal cognitive function (measured by
WCST)
Rybakowski et al. (2003)
Bipolar disorder Psychological Subthreshold mood lability Perugi & Akiskal (2002)
Depression Metabolic Occupancy of 5-HT1A autoreceptors by
pindolol
Rabiner et al. (2002)
Depression Metabolic Changes in the HPA axis Kuenzel et al. (2002)
Depression Metabolic Depressive response to tryptophan depletion Moreno et al. (2002)
Depression Psychological Personality Willis-Owen et al. (2005)
Schizophrenia Anatomical Cerebellar abnormalities Marcelis et al. (2003)
Schizophrenia Anatomical Olfactory bulb volumes Turetsky et al. (2003)
Schizophrenia Anatomical Ventricular enlargement Garver et al. (1999); McDonald et al. (2002)
Schizophrenia Anatomical Decreased grey matter in insular and left
entorhinal cortex
Yoneyama et al. (2003)
Schizophrenia Anatomical Temporal lobe grey matter abnormalities Dickey et al. (1999)
Schizophrenia Electrophysiological Exploratory eye movement Takahashi et al. (2003)
Schizophrenia Electrophysiological Event-related potential: mismatch
negativity amplitude
Michie et al. (2002); Umbricht et al. (2003);
Bramon et al. (2004)
Schizophrenia Electrophysiological Event-related potential: P300 and P50
responses
Blackwood (2000); Freedman et al. (2000);
Turetsky et al. (2000); Cadenhead (2002);
Cadenhead et al. (2002); Malone et al. (2002);
Myles-Worsley (2002); Raux et al. (2002)
Schizophrenia Metabolic Niacin skin test Smesny et al. (2003)
Schizophrenia Sensory Olfactory sensitivity Kanes et al. (2003)
Schizophrenia Psychological Personality Carmine et al. (2003a,b); Mityushina et al.
(2003)
Schizophrenia Psychological Event-related potential: prepulse inhibition Cadenhead et al. (1996, 1997, 1999); Braﬀ et al.
(2001); Swerdlow et al. (2002)
Schizophrenia Psychological Executive performance Dollfus et al. (2002)
Schizophrenia Psychological Spatial and verbal memory Cannon et al. (2001); Krabbendam et al. (2001);
Myles-Worsley & Park (2002); Tuulio-
Henriksson et al. (2002, 2003); Appels et al.
(2003); Gasperoni et al. (2003); Glahn et al.
(2003)
Schizophrenia Psychological Verbal and spatial attentional processes Chen & Faraone (2000); Cornblatt & Malhotra
(2001)
Schizophrenia Sensory Activity of magnocellular visual pathway Bedwell et al. (2003)
Schizophrenia Sensory Smooth pursuit eye movements Amador et al. (1995); Clementz et al. (1995);
Gooding et al. (2000); Curtis et al. (2001);
Ross et al. (2002); Rybakowski & Borkowska
(2002); Rybakowski et al. (2002); Calkins et al.
(2003, 2004); Gooding et al. (2003);
Kathmann et al. (2003); Ettinger et al. (2004,
2006); Ross et al. (2005)
ADHD, Attention deﬁcit hyperactivity disorder; CPT, Continuous Performance Test; WCST, Wisconsin Card Sorting Task.
The endophenotype concept 165psychiatric disease. In order to do so, we need to
establish criteria by which to assess whether a
phenotype is likely to be genetically tractable.
Genetic eﬀect sizes in psychiatric disorders
A critical measure of the genetic architecture of
a phenotype is the eﬀect size of a locus, by which
we mean the extent to which a locus contributes
to the variance of a phenotype or, as in the case
here when disease outcome is involved, the ex-
tent to which it increases the risk of disease
susceptibility. The power to detect an allele with
a given relative risk depends on the size of the
odds ratio, or percentage of phenotypic variance
explained, and also on the allele frequency.
For a locus with two alleles, power to detect
is maximal when the allele frequency is 0.5 and
the relative risk is large. This is the characteristic
we expect to ﬁnd at loci that contribute to dis-
ease susceptibility in a genetically tractable
phenotype.
Can we establish the eﬀect size that would
make detection relatively straightforward? In-
stead of an absolute criterion for eﬀect size,
we can instead establish a relative one: we can
compare the eﬀect sizes of loci that contribute to
psychiatric disease with those of loci contribu-
ting to variation in endophenotypes. Are the
latter larger? Our problem is that there are very
few robust estimates of the eﬀect sizes for sus-
ceptibility loci in either psychiatric disease
or endophenotypes. One approach to obtain
good estimates is to combine studies using meta-
analytical techniques.
Table 2 lists results from those meta-analyses
of candidate genes for susceptibility to schizo-
phrenia that found evidence of a positive genetic
association. The summary presented suggests
that genetic eﬀects are small. The average odds
ratio for the associations is 1.2, equivalent to
y0.2% of the phenotypic variance, a ﬁgure
consistent with that obtained from meta-
analyses of other complex traits (Ioannidis et al.
2001).
This odds ratio is useful as it allows us also to
estimate the size of studies needed to detect such
eﬀects and thereby assess the value of individual
studies. Table 3 illustrates the total number of
cases required (assuming that the total sample
would in addition include an equal number of
controls) in order to achieve 80% power to de-
tect a range of eﬀect sizes for a range of minor
allele frequencies. As we can see, the majority of
individual primary studies conducted are likely
to be grossly under-powered to detect eﬀect
sizes of the magnitude indicated by the meta-
analyses.
For the discussion that follows next, it is
important to consider the results of one negative
meta-analysis. We recently conducted a meta-
analysis of case-control genetic association
studies of the COMT Val
158/108 Met poly-
morphism in healthy control groups and clini-
cally diagnosed schizophrenia patients (Munafo
et al. 2005). The COMT gene has been regarded
as a promising candidate gene for schizophrenia
for some time, as it is the gene coding for the
catechol O-methyltransferase enzyme, which
inactivates catechols at post-synaptic sites in the
human brain. COMT contains a functional
polymorphism, a single nucleotide polymor-
phism at position 158/108 that results in a
change from valine (Val) to methionine (Met)
(Chen et al. 2004).
The results of our meta-analysis, which in-
cluded data from 18 published studies, did not
support an association between the COMT Val
allele and schizophrenia case status. We con-
cluded that if a genuine association exists be-
tween the COMT gene and schizophrenia, the
Table 2. Meta-analyses of case-control genetic association studies indicating possible
association with schizophrenia
Reference Year Gene Cases Controls kp value OR
Glatt et al. (2003) 2003 DRD2 3733 5373 24 0.007 1.3
Abdolmaleky et al. (2004) 2004 5-HT2A 4632 4410 31 0.015 1.1
Fan & Sklar (2005) 2005 SLC6A4 2177 2369 12 0.00014 1.2
Ma et al. (2006) 2006 G72/G30 1125 1126 2 0.001 1.2
Talkowski et al. (2006) 2006 RGS4 3486 3755 8 0.01 1.2
OR, Odds ratio.
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with the largest (albeit non-signiﬁcant) eﬀect
size observed in our meta-analysis being an odds
ratio of 1.13, accounting for less than 0.2% of
the phenotypic variance. Therefore, given a Val
allele frequency of 50% and a disease preva-
lence of 1%, a sample consisting of in excess of
900 cases and an equal number of controls
would be required to detect this eﬀect with 80%
power at a relatively non-conservative alpha of
0.05 (Table 3).
Can endophenotype measures aﬀord larger
eﬀect sizes?
We need next to examine the genetic architec-
ture of endophenotypes. We start by consider-
ing some of the most heavily investigated
endophenotypes in schizophrenia, measures of
neuropsychological dysfunction, and particu-
larly those that reﬂect activity in the prefrontal
and temporo-limbic systems (Cannon et al.
2000). Abnormalities of working memory, epi-
sodic learning, attention and reaction time
aggregate in the families of schizophrenia
patients and probably arise from a common
genetic susceptibility (Cannon et al. 2000), as
expected for an endophenotype of schizo-
phrenia.
One reason for the interest in working
memory is because it may reﬂect function in
the meso-cortical dopamine (DA) pathway.
Experimental manipulation of DA metabolism
by pharmacological challenge in humans and
animals supports the assumption that the DA
system is involved in cognition: reduced DA
transmission in the rat prefrontal cortex impairs
cortical-dependent cognition (Jentsch et al.
1997), administration of a selective inhibitor of
COMT improves cognitive function (including
working memory) in patients with Parkinson’s
disease (Gasparini et al. 1997), while injection of
D1 antagonists into the dorsolateral prefrontal
cortex impairs tasks that require working
memory (Sawaguchi & Goldman-Rakic, 1991;
Williams & Goldman-Rakic, 1995). As men-
tioned above, COMT plays an important role in
DA metabolism in the frontal cortex and the
Val/Met polymorphism is a critical factor in
determining COMT eﬃciency: the Val isoform
has higher activity which may lead to lower
synaptic DA levels in the prefrontal cortex
(Chen et al. 2004). Thus there is a strong prior
hypothesis that implicates DA regulation in
prefrontal cortical function, and particularly
that variation in COMT genotype could be
associated with an endophenotype of schizo-
phrenia, even if it is not associated with schizo-
phrenia case status (Munafo et al. 2005).
Consequently a number of investigators have
carried out genetic studies of COMT genotype
and cognitive function. These studies allow us to
compare the eﬀect sizes observed in case-control
studies of psychiatric disease with those ob-
served in endophenotype studies.
COMT genotype and Wisconsin Card Sorting
Task performance
We carried out a meta-analysis of published
studies reporting data on the association be-
tween COMT genotype and Wisconsin Card
Sorting Task (WCST) performance (in particu-
lar, perserverative errors), a recognized measure
ofprecorticalfunction(Goldberg&Weinberger,
1988). Recall that our recent meta-analysis of
COMT genotype and schizophrenia case status
Table 3. Power analysis
Prev. Alpha
Odds
ratio
Power 80% Power 90%
Minor allele frequency
0.10 .30 .50 .10 .30 .5
1% 0.05 2 139 69 67 186 93 90
1% 0.01 2 207 103 100 263 132 128
1% 0.001 2 302 151 147 370 185 179
1% 0.05 1.6 325 154 143 435 206 191
1% 0.01 1.6 483 229 212 616 292 270
1% 0.001 1.6 706 335 310 865 410 380
1% 0.05 1.2 2394 1066 929 3205 1426 1244
1% 0.01 1.2 3562 1586 1382 4538 2020 1761
1% 0.001 1.2 5208 2318 2021 6376 2838 2474
5% 0.05 2 127 64 62 169 85 83
5% 0.01 2 188 95 93 240 121 118
5% 0.001 2 275 139 135 337 170 166
5% 0.05 1.6 297 141 131 397 189 176
5% 0.01 1.6 442 211 196 563 268 249
5% 0.001 1.6 646 308 286 790 377 350
5% 0.05 1.2 2198 980 856 2942 1312 1145
5% 0.01 1.2 3270 1458 1273 4166 1857 1622
5% 0.001 1.2 4781 2131 1861 5853 2610 2279
10% 0.05 2 112 57 56 150 76 75
10% 0.01 2 166 85 83 212 108 106
10% 0.001 2 243 124 122 298 152 149
10% 0.05 1.6 264 126 118 353 169 158
10% 0.01 1.6 392 188 176 500 240 224
10% 0.001 1.6 573 275 257 702 337 315
10% 0.05 1.2 1964 878 768 2629 1175 1028
10% 0.01 1.2 2923 1306 1143 3724 1664 1456
10% 0.001 1.2 4273 1909 1671 5231 2338 2045
Prev., Prevalence.
The endophenotype concept 167(Munafo et al. 2005) described above did not
oﬀer any evidence in support of association be-
tween the gene and the disease, so a positive
association with the endophenotype would be
evidence that the endophenotype strategy is
more powerful, regardless of the eﬀect size.
Analysis of the association between COMT
genotype and WCST performance should pro-
vide a good test of the value of the endo-
phenotype approach in genetics.
We searched for relevant publications in
PubMed, PsycInfo and Medline, up to 31
May 2006, using the search terms ‘Wisconsin’,
‘card sorting’, ‘WCST’, ‘COMT’, ‘catechol
O-methyl transferase’. Bibliographies of all ar-
ticles obtained in this way were hand-searched
for additional references. Data extraction and
analysis procedures were similar to those em-
ployed in our previous meta-analyses (Munafo
et al. 2005). Brieﬂy, a ﬁxed-eﬀects framework,
using inverse variance methods, was employed
initially, and the assumption that the eﬀect of
allele frequency is constant across samples
checked using a x
2 test of goodness of ﬁt for
homogeneity. When there was evidence of sig-
niﬁcant association in the presence of signiﬁcant
between-sample heterogeneity, the analysis was
re-run using a random-eﬀects framework, using
Der Simonian and Laird methods.
A total of 16 studies (Egan et al. 2001; Bilder
et al. 2002; Joober et al. 2002; Malhotra et al.
2002; Mattay et al. 2003; Tsai et al. 2003; Rosa
et al. 2004; Taerk et al. 2004; Bruder et al. 2005;
Galderisi et al. 2005;Ho et al.2005; Lipsky et al.
2005; Minzenberg et al. 2006; Ohnishi et al.
2006; Rybakowski et al. 2006; Szoke et al. 2006)
published between 2001 and 2006 and compris-
ing 26 independent samples were identiﬁed by
the search strategy and met the inclusion criteria
(Table 4). Where data were not available in an
appropriate format for inclusion, we attempted
to contact authors directly. Data from two
studies (Egan et al. 2001; Taerk et al. 2004)
comprised normalized t scores (i.e. higher scores
Table 4. Studies of COMT genotype and WCST perseverative errors
Author Year Location Subjects Ethnicity
Met/Met Val/Met+Val/Val
Mean S.D. n Mean S.D. n
Egan et al. (2001) (a)a 2001 NIMH SZ European 34.00 7.41 28 38.13 14.99 147
Egan et al. (2001) (b)a 2001 NIMH Sibs of SZ European 45.00 8.74 39 45.25 12.68 183
Egan et al. (2001) (c)a 2001 NIMH Healthy European 45.00 4.43 10 50.67 7.80 45
Bilder et al. (2002) 2002 New York SZ Mixed 44.80 21.10 4 49.61 27.73 41
Joober et al. (2002) (a) 2002 Quebec SZ N.A.1 9 .42 16.87 18 34.05 25.10 76
Joober et al. (2002) (b) 2002 Quebec Healthy N.A.1 6 .19 20.29 13 10.47 10.75 18
Malhotra et al. (2002) 2002 NIMH Healthy Mixed 7.46 4.01 13 12.63 10.14 60
Tsai et al. (2003) 2003 Taipei Healthy Asian 14.20 8.00 6 17.76 11.41 114
Mattay et al. (2003) 2003 NIMH Healthy European 7.70 2.00 6 12.85 8.75 11
Rosa et al. (2004) (a) 2004 Barcelona SZ European 26.90 22.70 15 21.06 12.93 60
Rosa et al. (2004) (b) 2004 Barcelona Sibs of SZ European 11.20 7.30 16 17.40 13.44 63
Taerk et al. (2004)a 2004 Quebec ADHD N.A. 100.60 12.20 29 98.38 12.70 89
Galderisi et al. (2005) 2005 Naples SZ European 27.80 21.92 28 27.57 17.89 78
Bruder et al. (2005) 2005 New York Healthy Mixed 8.60 9.40 43 10.97 10.51 201
Ho et al. (2005) (a) 2005 Iowa Healthy European 8.22 5.92 18 7.45 4.33 66
Ho et al. (2005) (b) 2005 Iowa SZ European 12.49 10.16 38 11.75 7.30 121
Lipsky et al. (2005) 2005 Washington Brain injury Mixed 11.20 6.20 25 12.70 12.17 88
Ohnishi et al. (2006) (a) 2006 Tokyo SZ Asian Data not available Data not available
Ohnishi et al. (2006) (b) 2006 Tokyo Healthy Asian
Minzenberg et al. (2006) (a) 2006 New York SPD European 9.00 2.65 3 16.30 15.00 20
Minzenberg et al. (2006) (b) 2006 New York NSPD European 9.78 9.26 18 10.91 9.68 33
Minzenberg et al. (2006) (c) 2006 New York Healthy European 10.50 10.38 4 10.11 9.69 18
Rybakowski et al. (2006) 2006 Poland Healthy European 19.50 11.72 24 16.47 9.99 55
Szoke et al. (2006) (a) 2006 France SZ European 12.03 14.91 23 15.57 16.03 131
Szoke et al. (2006) (b) 2006 France BPD European 29.22 19.52 15 21.21 19.36 43
Szoke et al. (2006) (c)b 2006 France Healthy European 12.17 11.50 30 15.65 11.68 63
WCST, Wisconsin Card Sorting Task; NIMH, National Institute of Mental Health; SZ, schizophrenia; ADHD, attention deﬁcit hyper-
activity disorder; SPD, schizotypal personality disorder; NSPD, non-schizotypal personality disorder; BPD, bipolar disorder; N.A., not
available.
a Scoring of normalized t scores reversed to give consistent eﬀect size estimate.
b Includes healthy controls and unaﬀected ﬁrst-degree relatives of SZ and BPD patients.
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for consistency with other studies. One study
(Ohnishi et al. 2006), comprising two indepen-
dent samples, had to be excluded because we
could not obtain appropriate data.
A ﬁxed-eﬀects model indicated evidence
of association between COMT genotype and
WCST performance (k=24, Z=1.97, p=
0.048), with increased perseverative errors in the
Val/Met+Val/Val group compared to the Met/
Met group (d=0.10). There was no evidence of
between-sample heterogeneity [x
2(23)=30.06,
p=0.148]. These data are presented graphically
in Fig. 1.
Given evidence that the ﬁrst published study
of a genetic association frequently represents
an over-estimation of the true eﬀect size
(Trikalinos et al. 2004), we re-ran our analysis
excluding data from the three samples reported
in the ﬁrst published study (Egan et al. 2001).
This resulted in non-signiﬁcant evidence for as-
sociation (p=0.166) and a reduction in the
pooled eﬀect-size estimate (d=0.08).
Our meta-analysis shows that if a genuine
association exists between the COMT gene and
WCST performance, the likely eﬀect size is a
standardizedmeandiﬀerenceof0.10,accounting
for less than 0.5% of the phenotypic variance.
Therefore, given a Val allele frequency of 50%,
a sample consisting of in excess of 1700 subjects
would be required to detect this eﬀect with 80%
power at a relatively non-conservative alpha
of 0.05.
One potential criticism of the use of WCST
performance as a schizophrenia endophenotype
is that it reﬂects a complex behavioural pheno-
type which may only partially recruit prefrontal
function. A more cognitively ‘pure’ task which
more speciﬁcally recruits the prefrontal cortex
may, therefore, represent a better assay for the
purposes of genetic dissection. We consider
next one such phenotype, the N-Back working
memory task.
It is well-established that schizophrenia is as-
sociated with a deﬁcit in working memory (Lee
& Park, 2005), and is regarded as a cardinal
cognitive symptom. The N-Back task requires
participants to monitor a series of stimuli and
to respond whenever a stimulus is presented that
is the same as the one presented N trials pre-
viously, where N is a pre-speciﬁed integer,
usually 1, 2, or 3. The task requires online
monitoring, updating, and manipulation of
remembered information and therefore places
−1·00 −0·50 0·00 0·50 1·00
Egan (a) −0·293 0·207 0·043 −0·699 0·112 −1·419 0·156
Egan (b) −0·021 0·176 0·031 −0·366 0·325 −0·117 0·907
Egan (c) −0·773 0·357 0·128 −1·473      −0·072 −2·163 0·031
Bilder −0·176 0·524 0·275 −1·203 0·851 −0·336 0·737
Joober (a) −0·615 0·266 0·071 −1·136      −0·094 −2·312 0·021
Joober (b)   0·371 0·367 0·135 −0·349 1·090   1·010 0·312
Malhotra −0·551 0·309 0·096 −1·157 0·056 −1·780 0·075
Tsai −0·315 0·419 0·176 −1·137 0·506 −0·752 0·452
Mattay −0·712 0·522 0·272 −1·735 0·311 −1·363 0·173
Rosa (a)       0·382 0·290 0·084 −0·187 0·951   1·315 0·189
Rosa (b) −0·497 0·283 0·080 −1·051 0·057 −1·757 0·079
Taerk   0·176 0·214 0·046 −0·243 0·596   0·824 0·410
Galderisi   0·012 0·220 0·049 −0·420 0·444   0·055 0·956
Bruder −0·230 0·168 0·028 −0·559 0·100 −1·363 0·173
Ho (a)   0·164 0·266 0·071 −0·358 0·685   0·615 0·539
Ho (b)   0·092 0·186 0·035 −0·273 0·456   0·493 0·622
Lipsky −0·134 0·227 0·051 −0·579 0·310 −0·593 0·553
Minzenberg (a) −0·511 0·624 0·389 −1·733 0·712 −0·819 0·413
Minzenberg (b) −0·118 0·293 0·086 −0·693 0·456 −0·404 0·686
Minzenberg (c)   0·040 0·553 0·306 −1·044 1·123   0·072 0·943
Rybakowski   0·288 0·246 0·060 −0·194 0·769   1·170 0·242
Szoke (a) −0·223 0·226 0·051 −0·667 0·221 −0·985 0·325
Szoke (b)   0·413 0·302 0·091 −0·180 1·005   1·366 0·172
Szoke (c) −0·299 0·223 0·050 −0·736 0·137 −1·343 0·179
−0·104 0·053 0·003 −0·208      −0·001 −1·974 0·048
Egan (2001) (a) 
Egan (2001) (b) 
Egan (2001) (c)  
Bilder (2002)     
Joober (2002) (a)
Joober (2002) (b)
Malhotra (2002)   
Tsai (2003)      
Mattay (2003)
Rosa (2004) (a)     
Rosa (2004) (b)    
Taerk (2004)     
Galderisi (2005) 
Bruder (2005)
Ho (2005) (a)
Ho (2005) (b)
Lipsky (2005)
Minzenberg (2006) (a)
Minzenberg (2006) (b)
Minzenberg (2006) (c)
Rybakowski (2006)
Szoke (2006) (a)
Szoke (2006) (b)
Szoke (2006) (c)
S.D. (means) and 95% CI
Study name
(1st-named author)
Statistics for each study
S.D.
(means) S.E.
Lower
limit
Upper
limit Variance Z value p value
FIG. 1. Meta-analysis of association of COMT genotype with WCST performance (perseverative errors). Meta-analysis indicates
marginal evidence of association between COMT genotype and WCST performance, with a direction of eﬀect consistent with
increased perseverative errors in the Val/Met+Val/Val group compared to the Met/Met group. Bars represent individual study
95% conﬁdence intervals, with a central block proportional to study size. The summary diamond bar represents the summary
eﬀect size estimate and 95% conﬁdence interval.
The endophenotype concept 169demands on key processes within working
memory. Across studies, many diﬀerent types
of stimuli have been used via various input
modalities (visuospatial, auditory, and olfac-
tory) making demands on diﬀerent processing
systems.
A large number of studies have investigated
working-memory performance in schizophrenia.
Meta-analysis of these studies conﬁrms that task
performance is impaired in schizophrenia more
than in controls (Lee & Park, 2005), and fur-
thermore, working-memory tasks such as the
N-Back have been demonstrated in fMRI in-
vestigations to heavily recruit the prefrontal
cortex (Carpenter et al. 2000); working-memory
performance is also highly heritable (Ando et al.
2001). N-Back task performance phenotypes
satisfy the criteria for an endophenotype of
schizophrenia.
COMT genotype and N-Back performance
We carried out a meta-analysis of published
studies reporting data on the association be-
tween COMT genotype and N-Back perform-
ance. Recall that a potential criticism of our
analysis of WCST data is that the latter rep-
resent a complex behavioural phenotype which
only partially recruits prefrontal function.
Analysis of the association between COMT
genotype and N-Back performance allows us to
investigate an endophenotype that is less subject
to this criticism.
We searched for relevant publications in
PubMed, PsycInfo and Medline, up to 31 May
2006, using the search terms ‘N-Back’, ‘work-
ing memory’, ‘COMT’, ‘catechol O-methyl
transferase’. Data extraction and analysis pro-
cedures were identical to those described above.
A total of four studies (Goldberg et al. 2003;
Stefanis et al. 2004; Bruder et al. 2005;
Bertolino et al. 2006) published between 2003
and 2006 and comprising six independent
samples were identiﬁed by the search strategy
and met the inclusion criteria (Table 5). Where
data were not available in an appropriate for-
mat for inclusion, we attempted to contact
authors directly.
A ﬁxed-eﬀects model indicated marginal evi-
dence of association between COMT genotype
and N-Back performance (k=6, Z=1.96, p=
0.050), with a direction of eﬀect consistent with
decreased accuracy in the Val/Met+Val/Val
group compared to the Met/Met group (d=
0.12). There was evidence of signiﬁcant between-
sample heterogeneity [x
2(4)=18.44, p<0.002]
and when the analysis was re-run using a
random-eﬀects model the evidence for associ-
ation was no longer signiﬁcant (p=0.085).
These data are presented graphically in Fig. 2.
Assuming that a genuine association exists
between the COMT gene and N-Back perform-
ance, the likely eﬀect size indicated in our meta-
analysis is a standardized mean diﬀerence of
0.12, accounting for less than 0.5% of the
phenotypic variance. Therefore, given a Val
allele frequency of 50%, a sample consisting of
in excess of 1700 subjects would be required to
detect this eﬀect with 80% power at a relatively
non-conservative alpha of 0.05.
One further criticism of the data which we
present above is that the genetic architecture of
a WCST and N-Back performance may be more
complex than that of other endophenotypes.
Perhaps other endophenotypes, for example
those that involve physiological or anatomical
measures, are more proximal to their genetic
Table 5. Studies of COMT genotype and N-Back 2 performance (% accuracy)
Author Year Location Subjects Ethnicity
Met/Met Val/Met+Val/Val
Mean S.D. n Mean S.D. n
Goldberg et al. (2003) (a) 2003 NIMH SZ N.A.0 .54 0.22 39 0.48 0.23 109
Goldberg et al. (2003) (b) 2003 NIMH Sibs of SZ N.A.0 .72 0.19 57 0.67 0.20 198
Goldberg et al. (2003) (c) 2003 NIMH Healthy N.A.0 .78 0.18 50 0.76 0.19 152
Stefanis et al. (2004) 2004 Athens Healthy European 87.33 7.42 96 87.66 7.80 362
Bruder et al. (2005)a 2005 New York Healthy Mixed 3.65 0.66 66 3.66 0.55 335
Bertolino et al. (2006) 2006 Bari Healthy N.A.8 8 .17 7.47 14 79.24 6.40 48
NIMH, National Institute of Mental Health; SZ, schizophrenia; N.A., not available.
a Overall measure of sensitivity for detecting targets and avoiding non-targets (dk).
170 J. Flint and M. R. Munafo`antecedents. We consider next one such pheno-
type, the P300 event-related potential.
There has been considerable interest in event-
related potentials as a biological marker of
schizophrenia from the early 1970s (Roth &
Cannon, 1972) when reduced amplitude and
delayed latency of the P300 waveform were ﬁrst
reported. An auditory, visual, or somatosensory
random and salient stimulus is presented to
subjects who must make a response, such as
pressing a button. Around 300 ms after the
stimulus, an event-related potential can be de-
tected across the scalp. This P300 waveform re-
corded from the scalp has several components
that reﬂect selective attention and working
memory in response to an unexpected change in
the environment.
A large number of studies have investigated
the P300 in schizophrenia. Meta-analysis of
these studies conﬁrms that P300 amplitude re-
ductions and latency delays occur in schizo-
phrenia more than in controls (Bramon et al.
2005); furthermore P300 phenotypes are heri-
table (van Beijsterveldt & van Baal, 2002). P300
phenotypes satisfy the criteria for an endo-
phenotype of schizophrenia.
COMT genotype and schizophrenia P300
amplitude and latency
We carried out a meta-analysis of published
studies reporting data on the association be-
tween COMT genotype and P300 amplitude
and latency. Recall that a potential criticism of
our analysis of WCST and N-Back data is that
they do not represent a truly biological endo-
phenotype marker. Analysis of the association
between COMT genotype and P300 amplitude
and latency should provide a best-case scenario
for the value of the endophenotype approach
in genetics.
We searched for relevant publications in
PubMed, PsycInfo and Medline, up to 31 May
2006, using the search terms ‘P300’, ‘ERP’,
‘event-related potential’, ‘COMT’, ‘catechol O-
methyl transferase’. Data extraction and analy-
sis procedures were identical to those described
above.
A total of three studies (Gallinat et al. 2003;
Tsai et al. 2003; Bramon et al. 2006) published
between 2003 and 2006 and comprising six
independent samples were identiﬁed by the
search strategy and met the inclusion criteria
(Table 6). Where data were not available in an
appropriate format, we attempted to contact
authors directly, which resulted in all available
data being included in the meta-analysis.
A ﬁxed-eﬀects model indicated no evidence of
association between COMT genotype and P300
amplitude (k=6, Z=0.14, p=0.887) and la-
tency (Z=0.14, p=0.892), although the direc-
tion of eﬀect was consistent with increased
amplitude and latency in the Val/Met+Val/Val
group compared to the Met/Met group (d=0.02
and d=0.05 respectively). There was evidence of
signiﬁcant between-sample heterogeneity in the
case of amplitude [x
2(5)=11.99, p=0.035] but
not latency [x
2(5)=7.22, p=0.204]. These data
are presented graphically in Fig. 3.
The likely eﬀect size attributable to the
COMT gene, if genuine, is therefore a standard-
ized mean diﬀerence of 0.02, accounting for
y0.01% of the phenotypic variance.
S.D. (means) and 95% CI
−1·00 −0·50 0·00 0·50 1·00
Study name
(1st-named author)
Statistics for each study
S.D.
(means) S.E.
Lower
limit
Upper
limit Variance Z value p value
Goldberg (2003) (a) 0·264 0·187 0·035 –0·103 0·631 1·409 0·159
Goldberg (2003) (b) 0·253 0·151 0·023 –0·043 0·548 1·677 0·094
Goldberg (2003) (c) 0·107 0·163 0·027 –0·213 0·426 0·664 0·513
Stefanis (2004) −0·043 0·115 0·013 −0·268 0·182 −0·372 0·710
Bruder (2005) −0·018 0·135 0·018 −0·282 0·246 −0·130 0·896
Bertolino (2006) 1·344 0·327 0·107 0·703 1·984 4·111 0·000
0·124 0·063 0·004 0·000 0·248 1·960 0·050
FIG. 2. Meta-analysis of association of COMT genotype with N-Back performance (2-Back). Meta-analysis indicates marginal
evidence of association between COMT genotype and N-Back 2 performance, with a direction of eﬀect consistent with decreased
accuracy in the Val/Met+Val/Val group compared to the Met/Met group. Bars represent individual study 95% conﬁdence
intervals, with a central block proportional to study size. The summary diamond bar represents the summary eﬀect size estimate
and 95% conﬁdence interval.
The endophenotype concept 171We can summarize the results of the meta-
analyses by noting that the sample sizes required
to detect the genetic loci contributing to endo-
phenotypes are of equivalent size to those
required to analyse the cognate psychiatric dis-
ease. In short, we ﬁnd no evidence that the
genetic architecture of endophenotypes is any
simpler than that of psychiatric illness.
Conclusions
We have so far considered examples where we
consider there to be suﬃcient genetic data
available to arrive at an estimate of the eﬀect
size. Our conclusions, that the eﬀect sizes found
in genetic studies of endophenotypes are not
considerably greater than those found in
psychiatric diseases, may be biased because we
have been limited to studying the COMT locus,
or because so far no large eﬀects have been
found. The ﬁrst issue is diﬃcult to tackle.
Signiﬁcant associations reported for other gen-
etic loci are based on either a single, or a very
small number, of studies, so that we do not yet
know how robust these ﬁndings are.
Two examples illustrate the point. The ﬁrst
concerns fMRI measures which are diﬃcult to
obtain in large numbers of people. Hariri and
colleagues reported that a polymorphism in the
serotonin transporter gene (5-HTT) was associ-
ated with the response of the amygdala to
fearful stimuli (Hariri et al. 2002). In a com-
parison of two groups of 14 individuals, carriers
of the s allele at the 5-HTT gene promoter were
found to exhibit an increased amygdala fearful
response compared with those homozygous for
the l allele (Hariri et al. 2002): the means of the
two groups were 0.28 (S.D.=0.22) and 0.03
(S.D.=0.19) with respect to % blood-oxygen-
level-dependent (BOLD) signal change for
fearful stimuli compared to neutral stimuli. In
comparison with the data we have reviewed, this
represents an enormous eﬀect size (equivalent
to y40% of phenotypic variance) that could
be detected at a signiﬁcance threshold of 0.05
with just 18 subjects. This ﬁnding could be due
to chance statistical ﬂuctuation. Indeed, a sub-
sequent study of 92 individuals (including 19
from the ﬁrst study) carried out by the same
group again showed a signiﬁcant eﬀect, but with
a reduction in the eﬀect size. The reported mean
values were this time 0.16 and 0.03 for the two
groups (Hariri et al. 2005), equivalent to an
eﬀect size of just over 10% of the phenotypic
variance. Additional studies are needed to con-
ﬁrm whether the eﬀect is indeed this large.
The second example is the investigation into
the genetic basis of an event-related potential,
the P50. This is another endophenotype for
schizophrenia, in which two stimuli are pre-
sented. At interstimulus intervals exceeding 8 s,
two event-related potentials are detected. If the
Table 6. Studies of COMT genotype and P300 amplitude and latency
Author Year Location Subjects Ethnicity
Met/Met Val/Met+Val/Val
Mean S.D. n Mean S.D. n
Amplitude
Tsai et al. (2003) 2003 Taipei Healthy Asian 11.30 6.00 6 9.00 3.67 49
Gallinat et al. (2003) (a) 2003 Germany SZ European 11.50 6.10 17 15.31 6.37 141
Gallinat et al. (2003) (b) 2003 Germany Healthy European 13.40 5.60 48 14.19 6.15 36
Bramon et al. (2006) (a) 2006 London SZ N.A.1 0 .72 7.24 16 7.95 6.76 46
Bramon et al. (2006) (b) 2006 London Sibs of SZ N.A.1 0 .01 6.02 27 10.59 6.46 64
Bramon et al. (2006) (c) 2006 London Healthy N.A.1 7 .06 8.05 13 12.67 8.07 24
Latency
Tsai et al. (2003) 2003 Taipei Healthy Asian 290.30 18.50 6 317.71 31.72 49
Gallinat et al. (2003) (a) 2003 Germany SZ European 316.60 32.80 17 318.00 32.45 141
Gallinat et al. (2003) (b) 2003 Germany Healthy European 324.80 44.00 48 328.28 37.41 36
Bramon et al. (2006) (a) 2006 London SZ N.A. 383.62 57.18 16 391.10 53.29 46
Bramon et al. (2006) (b) 2006 London Sibs of SZ N.A. 416.61 50.04 28 394.81 60.89 66
Bramon et al. (2006) (c) 2006 London Healthy N.A. 357.77 51.72 13 357.15 53.21 24
SZ, Schizophrenia; N.A., not available.
172 J. Flint and M. R. Munafo`second stimulus occurs within 8 s of the ﬁrst,
normal subjects inhibit the response to the sec-
ond stimulus. Schizophrenia subjects have a
deﬁcit in such inhibition, a ﬁnding supported by
a recent meta-analysis (Bramon et al. 2005). The
diﬀerence in inhibition is maximal when the se-
cond stimulus follows the ﬁrst by 500 ms (Adler
et al. 1982).
Interest in the molecular basis of the P50
phenotype was spurred by a 1997 report that a
locus on chromosome 15 had been identiﬁed by
linkage mapping (Freedman et al. 1997). The
report was important because the locus con-
tained a gene, the alpha 7-nicotinic acid recep-
tor, which was later reported by the same group
to be signiﬁcantly associated with failure to
inhibit the P50 auditory-evoked potential
(Leonard et al. 2002). Furthermore, the group
has presented evidence that functional variants
in the promoter of the gene are present at sig-
niﬁcantly greater frequencies in schizophrenia
subjects compared to controls (Leonard et al.
2002). A second group has independently
reported that a 2 bp deletion in exon 6 of the
gene and a polymorphism in the promoter
are associated with the P50 phenotype (Raux
et al. 2002; Houy et al. 2004) but not with
schizophrenia. Clearly, given the ﬁndings for
other complex traits, these results must be
replicated in large samples if they are to be
regarded as genuine.
The two examples encourage the view that
some endophenotypes may be more genetically
tractable than the ones we have discussed. Our
concern is that as additional data accumulate
these ﬁndings may turn out to be false positives,
or at least the eﬀect sizes will be much smaller
than initially reported, as has often been found
with genetic association studies (Trikalinos et al.
2004). Indeed, removing samples from the ﬁrst
published study in our analysis of WCST data
rendered the association with COMT genotype
non-signiﬁcant and reduced the pooled eﬀect
size estimate by 20%.
The second issue is whether the current failure
to ﬁnd large genetic eﬀects in endophenotypes
can be read as a general indication of the com-
plexity of genetic architecture for all pheno-
types. Endophenotypes are assumed to have a
relatively simple genetic architecture because
there are relatively few pathways from gene to
phenotype. The consequence is that sequence
−1·00 −0·50 0·00 0·50 1·00
Tsai (2003) 0·582 0·435 0·190 −0·272 1·437 1·336 0·162
Gallinat (2003) (a) −0·601 0·258 0·067 −1·108 −0·093 −2·320 0·020
Gallinat (2003) (b) −0·135 0·221 0·049 −0·538 0·297 −0·613 0·540
Bramon (2004) (a) 0·402 0·292 0·095 −0·171 0·976 1·376 0·138
Bramon (2005) (b) −0·092 0·230 0·053 −0·542 0·368 −0·399 0·680
Bramon (2006) (c) 0·544 0·360 0·123 −0·142 1·231 1·555 0·120
−0·016 0·112 0·013 −0·236 0·204 −0·142 0·887
S.D. (means) and 95% CI
Study name
(1st-named author)
(a)
(b)
Statistics for each study
S.D.
(means) S.E.
Lower
limit
Upper
limit Variance Z value p value
−1·00 −0·50 0·00 0·50 1·00
Tsai (2003) −0·892 0·441 0·194 −1·796 −0·008 −2·024 0·043
Gallinat (2003) (a) −0·043 0·257 0·066 −0·546 0·460 −0·168 0·867
Gallinat (2003) (b) −0·084 0·221 0·049 −0·517 0·348 −0·382 0·703
Bramon (2004) (a) −0·138 0·291 0·084 −0·707 0·432 −0·474 0·635
Bramon (2005) (b) 0·376 0·227 0·062 −0·089 0·822 1·667 0·066
Bramon (2006) (c) 0·012 0·344 0·119 −0·953 0·987 0·034 0·973
−0·015 0·111 0·012 −0·234 0·203 −0·136 0·892
S.D. (means) and 95% CI
Study name
(1st-named author)
Statistics for each study
S.D.
(means) S.E.
Lower
limit
Upper
limit Variance Z value p value
FIG. 3. Meta-analysis of association of COMT genotype with P300 amplitude and latency. Meta-analysis indicates no evidence of
association between COMT genotype and P300 amplitude (a) and latency (b), with a direction of eﬀect consistent with increased
amplitude and latency in the Val/Met+Val/Val group compared to the Met/Met group. Bars represent individual study 95%
conﬁdence intervals, with a central block proportional to study size. The summary diamond bar represents the summary eﬀect size
estimate and 95% conﬁdence interval.
The endophenotype concept 173variants interact relatively directly with the
phenotype so the correlation should be easier to
detect. We have so far examined this assump-
tion by investigating what is known about the
genetic architecture of commonly investigated
endophenotypes, and have shown that there is
little evidence that it is considerably simpler
than that of psychiatric disease. Perhaps we
happen to have selected those phenotypes that
have a complex genetic architecture. In the ab-
sence of detailed genetic analyses of multiple
endophenotypes we cannot gainsay this point.
However, we are able to approach this question
from another point of view. We can ask what
is known about the genetic architecture of
phenotypes which have a much closer relation-
ship to their genetic basis than endophenotypes
for psychiatric disease.
Analyses of model organisms provide the rel-
evantinformation.Wewilldiscusstwoexamples.
The ﬁrst is genetic analysis of phenotypes in
the mouse, from which we have robust genome-
wide association data for multiple phenotypes,
behavioural and physiological, and associated
estimates of locus eﬀect sizes. These data allow
us to compare the genetic architecture of behav-
ioural phenotypes with those that would qualify
as endophenotypes: for instance measures of
electrophysiology, biochemistry, haematology
and immunology. The drawback is that mouse
models of psychiatric disease are imperfect, so
that inferences drawn from the mouse data may
be misleading. Nevertheless, we have no reason
to expect the relationship between endopheno-
types and behavioural phenotypes to be diﬀer-
ent in rodents and humans.
Reviews of the distribution of locus eﬀect
sizes show no diﬀerence between physiological
and behavioural phenotypes (Flint et al. 2005).
Moreover, in the most detailed analysis to date
of the genetic architecture of complex traits in
the mouse, among phenotypes there was no
signiﬁcant diﬀerence in the number or eﬀect
size of loci detected (Valdar et al. 2006).
Intriguingly, regardless of the phenotype, the
genetic eﬀects that were detected explained
about the same proportion of the additive vari-
ance, suggesting considerable similarity in the
genetic architecture of many phenotypes
(Valdar et al. 2006). Fig. 4 shows the eﬀect sizes
of 843 quantitative trait loci (QTL). The
phenotypes include measures of anxiety and
learning and memory, as well as haematology,
immunology, biochemistry, physiology and
anatomy. A full description is given in Valdar
et al. (2006) and on a website (http://gscan.
well.ox.ac.uk). Fig. 4 shows that preponderance
of small eﬀects. For each of the 100 phenotypes
analysed, many loci contribute a small pro-
portion to the variance. Large eﬀect QTL are
rare: only ten account for greater than 5% of
phenotypic variance, and the mean is 2.2%.
The mouse data indicate that we would not
have obtained a simpler genetic architecture by
working with any of the physiological, im-
munological, biochemical or haematological
phenotypes in place of the behavioural pheno-
types. We would still face the currently de-
manding challenge of having to identify the
molecular basis of many small genetic eﬀects.
The second example addresses the question of
the relationship between genetic variants and
phenotypes at an extremely immediate level,
namely the correlation between DNA sequence
variants and variation in the relative abundance
of mRNA. Variation in transcript abundance is
heritable and it is reasonable to expect that the
variation in expression of some genes may cor-
relate with psychiatric disease. Thus a gene ex-
pression proﬁle could act as an endophenotype,
although currently we do not know which genes
show expression patterns correlated with psy-
chiatric disease. Compared to any of the
endophenotypes so far analysed (Table 1), vari-
ation in the amount of transcript is more
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FIG. 4. Distribution of eﬀect sizes of 843 mouse quantitative
trait loci (QTL).
174 J. Flint and M. R. Munafo`proximal to DNA sequence variation and, if the
assumptions about the nature of an endo-
phenotype are correct, the genetic architecture
of transcript variation should be relatively
simple.
Analyses of gene expression variation in
yeast, rodents and humans concur in ﬁnding
that the genetic architecture of gene expression
is polygenic and that the genetic eﬀects are
relatively small (Morley et al. 2004; Brem &
Kruglyak, 2005; Chesler et al. 2005; Hubner
et al. 2005). In yeast, where we have the most
reliable estimates, relatively few transcripts
have large eﬀects: the median eﬀect size was
equivalent to 27% of variation in transcript
level, only 16% of loci accounted for more than
60% of variation, and a quarter explained less
than 10% (Brem & Kruglyak, 2005). Although
estimates of eﬀect size are not as robust in
rodents, the available data indicate that the
eﬀect sizes are comparable to those found in
yeast (Morley et al. 2004; Chesler et al. 2005;
Hubner et al. 2005).
Although the eﬀect sizes of loci contributing
to variation in mRNA transcript abundance are
larger than the eﬀects found in complex traits
(which explain less than 1% of the phenotypic
variance) eﬀect sizes are relative to the popu-
lation in which they are measured. A reasonable
comparison for the rodent mRNA data is with
the eﬀect sizes of QTL found in crosses between
inbred strains of mice. Remarkably, the median
eﬀect size of QTL is 12% (Flint et al. 2005), just
under half that of the expression phenotypes.
Therefore, even when we consider a phenotype
that is directly linked to the genetic constitution
of the organism, genetic architecture is not
radically diﬀerent from complex phenotypes.
We have reviewed what is known about the
genetic basis of endophenotypes and shown that
their genetic architecture may be as complex
as that of psychiatric disease. This does not
mean there is no advantage to the use of endo-
phenotypes for genetic studies. We have pointed
out that the robust, quantitative measures that
are typical of many endophenotypes means that
they may be suitable for collecting the large
samples needed for genetic analysis of complex
traits, and may aﬀord more statistically reliable
data. We suggest that, along with the frequency
and penetrance of a disease-causing allele
given in Table 3, the ease and reliability of
phenotyping should be factored into power cal-
culations.
There are important limitations to our
analysis. First, we have little reliable data about
the genetic basis of complex traits in general
and psychiatric endophenotypes in particular.
Assumptions about the genetic architecture of
complex traits depend so far largely on negative
ﬁndings: our inability to detect robust linkage
and association signals is due to lack of power
and we have not suﬃciently appreciated the
genetic complexity. It is possible that, with the
completion of the ﬁrst whole genome associ-
ation studies when estimates of eﬀect size across
the genome are available, a diﬀerent picture
will emerge. A second important limitation is
that our review has concentrated on the eﬀect
of COMT on endophenotypes. Unfortunately
there are no other examples where suﬃcient
data have accumulated to be included in meta-
analyses. Again, the availability of additional
data might alter our results.
However, we think that our conclusions are
unlikely to change much: ﬁrst, studies in
genetically more tractable organisms, such as
yeast, ﬂies and rodents, conﬁrm the ﬁnding of
genetic complexity for all phenotypes. The
results are not here based on negative results: we
have deﬁnite evidence of complexity. Second, as
we have shown in the example of the genetic
analysis of transcriptional abundance, there is
no indication that alternative phenotypes will
be any easier to deal with. Thus, while endo-
phenotypes may be useful for many reasons,
such as providing trait markers of susceptibility
to psychiatric illness, for providing biological
markers of disease and models for investigating
disease process, we do not think they are likely
to be any easier to dissect at a genetic level than
the disorders to which they are related.
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